Cited by 255RNA Interference and Gene DeliveryRNA and protein synthesis mechanismsNanoparticle-Based Drug Delivery

Emerging mRNA technologies: delivery strategies and biomedical applications

Xiao, Yufen, Tang, Zhongmin, Huang, Xiangang, Chen, Wei, Zhou, Jun, Liu, Haijun, Liu, Chuang, Kong, Na +1 more·2022·Chemical Society Reviews

Abstract

This review highlights significant progress in mRNA delivery platforms and therapeutic applications from the view of chemistry. Insights into the challenges and future development towards clinical translation of mRNA therapeutics are also provided.

Integrity signals

Registry

Crossref · 10.1039/d1cs00617g

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines and have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results.

    “Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Xiao, Y., Tang, Z., Huang, X., Chen, W., Zhou, J., Liu, H., Liu, C., Kong, N., & Tao, W.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
  • Kong, Na
  • Tao, Wei
Venue
Chemical Society Reviews
Published
2022
Volume
51
Issue
10
Pages
3828-3845
ISSN
  • 0306-0012 (ISSN-L)
  • 1460-4744
OpenAlex
W4224231957
Cited by
255
References
11
Citations by year
2026: 49 · 2025: 77 · 2024: 59 · 2023: 47 · 2022: 23
FWCI
5.36
Type
journal article
Language
en
Open access
closed
Locations
  • Chemical Society Reviews (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Harvard Medical School (No. 2420 BPA075)
  • American Heart Association (No. 2018A004190)
  • National Natural Science Foundation of China (82122076)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
mRNA delivery, mRNA vaccines, cancer immunotherapy, genome editing, clinical translation, lipid nanoparticles
MeSH terms
COVID-19, Humans, Immunotherapy, Proteins, RNA, Messenger, Nanoparticles, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review